Skip to main content

Australia's Victoria state to ease COVID-19 restrictions as cases slow

By Unknown

Victoria, Australia's second most populous state and the epicentre of the country's COVID-19 outbreak, will accelerate the easing of social distancing restrictions as infections slow to fewer than 20 cases a day, its premier said on Sunday.

Victoria, which reported 16 COVID-19 cases in the past 24 hours, has placed nearly 5 million residents of its capital Melbourne under one of the world's most stringent lockdowns since early August.

With cases well below the record one-day high of more than 700 cases reported in August, state Premier Daniel Andrews said some curbs, including a night curfew, will be removed almost immediately.

The remaining curbs could be relaxed earlier, with restrictions eased when case numbers hit certain triggers. Victoria state previously said most restrictions would remain in place until the end of November.

"We are ahead of schedule, we have made more progress than we hoped to make at this point in time," Andrews told reporters in Melbourne.

"But it doesn't mean this is over."

The accelerated timetable for removing restrictions across Victoria is a boost to Australia's ailing economy. The outbreak in Victoria dented any hope of a quick economic rebound as Australia enters its first recession in three decades and effective unemployment tops 10%.

In an immediate boost to the economy, Victoria state said 127,000 workers will be allowed to return to work on Monday, a rise of 30,000 on its previous plan announced earlier this month.

More than 1 million people in Victoria have been receiving wage subsidies from the federal government after large swathes of the state were ordered to shut in August to slow the spread of the virus.

The restrictions, however, have prevented a national second wave of the virus.

Australia's most populous state, New South Wales on Sunday reported its first day without a COVID-19 case in more than three months.

Australia has reported just over 27,000 cases, and 872 deaths, well below the numbers seen in many other developed nations.


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown
Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more